Analysis of autologous hemopoietic stem cell transplantation for 61 patients with hematological malignancies
10.3760/cma.j.issn.1009-9921.2010.12.008
- VernacularTitle:自体造血干细胞移植治疗恶性血液病61例疗效分析
- Author:
Jie PENG
;
Yajing XU
;
Gan FU
;
Yi LIU
;
Yan CHEN
;
Yan ZHU
;
Qun HE
;
Wei LIU
;
Dengshu WU
;
Xielan ZHAO
;
Meizuo ZHONG
;
Fangping CHEN
- Publication Type:Journal Article
- Keywords:
Hemopoietic stem cell transplantation;
Hematologic neoplasms;
Complications;
Disease free survival
- From:
Journal of Leukemia & Lymphoma
2010;19(12):728-731
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical outcome of autologous hemopoietic stem cell transplantation (AHSCT) for hematological malignancies. Methods Data of 61 patients with hematological malignancies who underwent AHSCT in Xiangya Hospital from April 1994 to August 2008 were retrospectively analyzed. There were 30 acute non-lymphoblastic leukemias (ANLL), 25 non-Hodgkin lymphoma (NHL), 3 Hodgkin lymphoma (HL), and 3 plasmacytoma. Mel 160 mg/m2 + Ara-C 2.0/2.5 g × 2 +Cy 1.8 g/m2 × 2, or TBI 8-10 Gy + Cy 1.8 g/m2 × 2 were mainly included in pretreatment regimens. Results All patients had rapid hemopoietic reconstitution. There was one patient who died of heart failure during the transplantation process. The rate of AHSCT related death was 1.6 %. The median follow up duration was 52(2-211) months. Forty-seven of 61 patients were still alive during the analysis. The probabilities of disease free survival (DFS) at 5 years were significantly different between these two groups: (77.5±5.5) % for AHSCT groups and (31.6±7.3) % for synchronous intensive chemotherapy groups(P ＜0.01). Conclusion AHSCT can be safely performed as an important treatment constituent for hematological malignancies.
